2013
DOI: 10.4274/tjh.2012.55706
|View full text |Cite
|
Sign up to set email alerts
|

In response to “Megadose Methylprednisolone (MDMP) for Hemangiomatosis”

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2016
2016
2016
2016

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 3 publications
(3 reference statements)
0
1
0
Order By: Relevance
“…In cases with IH and Kasabach-Merritt syndrome resistant to conventional steroid treatment, highdose MPZ (30-100 mg/kg/day starting dose) have been shown to be effective 13,14 . However, the use of systemic corticosteroids is limited due to the potential for numerous side effects, including growth delay, cushingoid appearance, behavioral changes, irritability, gastrointestinal disturbance, hypertension, adrenal insufficiency, and compromised immunity 15 .…”
Section: Steroidsmentioning
confidence: 99%
“…In cases with IH and Kasabach-Merritt syndrome resistant to conventional steroid treatment, highdose MPZ (30-100 mg/kg/day starting dose) have been shown to be effective 13,14 . However, the use of systemic corticosteroids is limited due to the potential for numerous side effects, including growth delay, cushingoid appearance, behavioral changes, irritability, gastrointestinal disturbance, hypertension, adrenal insufficiency, and compromised immunity 15 .…”
Section: Steroidsmentioning
confidence: 99%